Literature DB >> 2461007

Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice.

M Lafon1, H Bourhy, P Sureau.   

Abstract

Protection experiments were performed in mice with different inactivated vaccines prepared with the fixed rabies virus strains: PM (Pitman-Moore), PV4 (Pasteur virus) and LEP (Flury LEP) against an intracerebral challenge with a European bat virus (Duvenhage, strain Hamburg, DUV3). All vaccines protected mice against challenge with CVS (Challenge virus standard). Vaccines prepared with PV4 protected mice against a DUV3 challenge. On the contrary, PM or LEP vaccines did not protect mice against a DUV3 infection. The protection conferred by PV4 vaccines against Duvenhage could be due to the antigenic relationship which seems to exist between PV4 and European bat virus as revealed by serum-virus neutralization, absorption experiments and CTL crossreactivity. The four virus strains PAS, PV4, PM and CVS, originated from the Pasteur virus isolated in 1882 from the brain of a rabid cow, were classified in two groups on the basis of reactivity with neutralizing anti-glycoprotein monoclonal antibodies. One group contained the L. Pasteur (PAS) and the PV4 strains, the second contained PM and CVS strains. The divergence between the two virus groups possibly resulted from distinct passage histories.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461007     DOI: 10.1016/0264-410x(88)90184-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  New aspects of rabies with emphasis on epidemiology, diagnosis, and prevention of the disease in the United States.

Authors:  J S Smith
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

2.  Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity.

Authors:  H Badrane; C Bahloul; P Perrin; N Tordo
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Up-regulation of Fas ligand (FasL) in the central nervous system: a mechanism of immune evasion by rabies virus.

Authors:  Leïla Baloul; Serge Camelo; Monique Lafon
Journal:  J Neurovirol       Date:  2004-12       Impact factor: 2.643

Review 4.  Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses.

Authors:  Venice Du Pont; Richard K Plemper; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2019-02-10       Impact factor: 7.090

5.  Quantifying antigenic relationships among the lyssaviruses.

Authors:  D L Horton; L M McElhinney; D A Marston; J L N Wood; C A Russell; N Lewis; I V Kuzmin; R A M Fouchier; A D M E Osterhaus; A R Fooks; D J Smith
Journal:  J Virol       Date:  2010-09-08       Impact factor: 5.103

6.  Chimeric lyssavirus glycoproteins with increased immunological potential.

Authors:  C Jallet; Y Jacob; C Bahloul; A Drings; E Desmezieres; N Tordo; P Perrin
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

7.  Antigenic and molecular characterization of bat rabies virus in Europe.

Authors:  H Bourhy; B Kissi; M Lafon; D Sacramento; N Tordo
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

8.  T and B cell human responses to European bat lyssavirus after post-exposure rabies vaccination.

Authors:  M Herzog; C Fritzell; M Lafage; J A Montaño Hirose; D Scott-Algara; M Lafon
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

9.  Diversity and epidemiology of Mokola virus.

Authors:  Joe Kgaladi; Nicolette Wright; Jessica Coertse; Wanda Markotter; Denise Marston; Anthony R Fooks; Conrad M Freuling; Thomas F Müller; Claude T Sabeta; Louis H Nel
Journal:  PLoS Negl Trop Dis       Date:  2013-10-24

10.  Pathogenicity and Immunogenicity of Recombinant Rabies Viruses Expressing the Lagos Bat Virus Matrix and Glycoprotein: Perspectives for a Pan-Lyssavirus Vaccine.

Authors:  Joe Kgaladi; Milosz Faber; Bernhard Dietzschold; Louis H Nel; Wanda Markotter
Journal:  Trop Med Infect Dis       Date:  2017-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.